In several in vitro and in vivo studies of MS, the knockdown or knockout of ERβ largely eliminates the beneficial actions of ERβ-selective agonist/ligands, indicating the central role of this ER subtype as a mediator of their efficacy in reversing this disease6–9. The gene discussed is ESR2; the disease is myeloid sarcoma.